glp-1 receptors Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP‑1 Receptor Agonists and Preclinical

Earlier this month, the White House announced that it would expand Medicare coverage for GLP-1 medications, including for obesityan about-face from its policy earlier this year

People with type 2 diabetes may be able to stop taking metformin with the supervision of a doctor

People with cardiovascular disease

Starting a GLP-1 medication while taking these drugs can still produce weight loss, but the results may be moderated

A number of studies dedicated to GLP-1RA efficacy in T2D included patients with chronic HF (CHF) (16.2% in the EXSCEL trial, 23.6% in SUSTAIN-6, 12.2% in PIONEER, 8.6% in REWIND, 20% in Harmony, 22% in ELIXA and 18% in LEADER)

Galindo is supported in part by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institute of Health (NIH) under award numbers P30DK111024, 1K23DK123384, 1R03DK138255, and 1U2CDK137135